Nature Reviews Drug Discovery contents November 2012 Volume 11 Number 11 pp 813-886

Advertisement
Don't wash away your cells! Tecan's HydroSpeed™ Year-to-End Offer!  • HydroSpeed plate washer offers extra gentle Cell Protection™ • wash settings  • High cell recovery using tuneable aspiration settings  • Anti-Clogging™ function for reliable ELISA washing  Click for YOUR offer
TABLE OF CONTENTS
November 2012 Volume 11 Number 11		Advertisement
Impact Factor 29.008 * The publication of this issue was delayed due to Hurricane Sandy closing our New York offices temporarily. We apologize for any inconvenience caused.	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month Article series: Case Histories  Featured article: MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles Eva van Rooij & Eric N. Olson	Proseek® Protein Biomarker Discovery Service Look deeper into the proteome. Promising Discoveries; analyze biomarkers in multiplex reactions using just a few microliters of sample. Delivering quality data; analyze up to 96 biomarkers in parallel with excellent analytical performance. www.olink.com
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Europe's largest dedicated antibody engineering & discovery meeting, Optimize 2013 (25-27th February 2013, Frankfurt), is specifically designed to explore the latest advances in antibody techniques to help you achieve lead differentiation and create superior drugs. Join us, along with leading clinical minds and pioneering drug developers to openly and frankly discuss how to maximise the quality of your antibody candidate entering into the clinical phase. Register now Download the brochure
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.
Advertisement
In this issue p813 | doi:10.1038/nrd3889 Full Text
Comment: EU-AIMS: a boost to autism research Declan Murphy & Will Spooren p815 | doi:10.1038/nrd3881 Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Cholesterol-lowering blockbuster candidates speed into Phase III trials Asher Mullard p817 | doi:10.1038/nrd3879 Less than a decade on from genetic studies indicating the potential of PCSK9 as a target to affect cholesterol metabolism, two PCSK9 inhibitors are moving into late-stage development. PDF
New class of kinase inhibitors poised to join the anticancer arsenal Alisa Opar p819 | doi:10.1038/nrd3880 Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine them with other cancer therapies. PDF
NEWS IN BRIEF Drug candidates selected for pioneering Alzheimer's prevention trial | GPCR researchers win chemistry Nobel p821 | doi:10.1038/nrd3887 PDF
BIOBUSINESS BRIEFS Deal watch: J&J and Genmab deal to push forward CD38 as a blood cancer target Alexandra Flemming p822 | doi:10.1038/nrd3890 PDF
BIOBUSINESS BRIEFS Deal watch: 'Big data' deal for diabetes clinical trial modelling Charlotte Harrison p822 | doi:10.1038/nrd3891 PDF
PATENT WATCH Indian patent office throws out Sutent patent | Migraine combo drug patents upheld | Patent opposition database launched | BRAF inhibitors Charlotte Harrison p824 | doi:10.1038/nrd3888 PDF
AN AUDIENCE WITH Garry Neil p826 | doi:10.1038/nrd3886 Garry Neil, acting CEO of TransCelerate, discusses the new precompetitive venture's aims to make clinical trials more efficient. PDF
FROM THE ANALYST'S COUCH Wet AMD market Basharut A. Syed, James B. Evans & Leonard Bielory p827 | doi:10.1038/nrd3790 The market for drugs to treat wet age-related macular degeneration (AMD) is expected to more than double by 2016. This article investigates unmet needs and discusses current agents in the pipeline. PDF
RESEARCH HIGHLIGHTS Top Alzheimer's disease: JNK3 as new target in AD? p829 | doi:10.1038/nrd3876 PDF Metabolic disorders: New avenue to AMPK activation p830 | doi:10.1038/nrd3872 PDF G protein-coupled receptors: Expanding the detection of GPCR activation p830 | doi:10.1038/nrd3874 PDF Anticancer drugs: A deeper understanding of VEGFR inhibitors p831 | doi:10.1038/nrd3873 PDF G protein-coupled receptors: Pioneering peptide GPCR structure determined p832 | doi:10.1038/nrd3875 PDF IN BRIEF Bone disorders: Clopidogrel prevents bone loss | Viral infection: Single antibody loop can neutralize influenza A | Immune regulation: Modulating monocytes could benefit ALS | Anticancer drugs: A new target for ovarian cancer PDF Drug Discovery JOBS of the week Post-doctoral Fellows in Drug Transport College of Pharmacy at the University of Oklahoma Health Sciences Center Drug Development Project Manager Cancer Research UK Director Research and Drug Development Children's Tumor Foundation Laboratory Head Drug Metabolism within Early and Investigative Drug Disposition and Safety (eiDDS) F. Hoffmann-La Roche AG Postdoc in drug delivery, nanotechnology, and biomaterials University of Michigan More Science jobs from Drug Discovery EVENT Active Pharmaceutical Ingredient (API) and Drug Product Specifications 12.-14.12.12 Berlin, Germany More science events from
Advertisement
Patient-Derived Xenograft Resource from JAX® Mice & Services Our patient-derived xenograft resource represents a significant improvement over existing cancer models. Tumors engrafted into the NSG mice closely match patient tumors in histology, gene expression and genetic markers. Learn more today.
PERSPECTIVES		Top
OPINION Drug repositioning for Alzheimer's disease Anne Corbett, James Pickett, Alistair Burns, Jonathan Corcoran, Stephen B. Dunnett, Paul Edison, Jim J. Hagan, Clive Holmes, Emma Jones, Cornelius Katona, Ian Kearns, Patrick Kehoe, Amrit Mudher, Anthony Passmore, Nicola Shepherd, Frank Walsh & Clive Ballard p833 | doi:10.1038/nrd3869 Preclinical research indicates that various drugs approved for indications such as hypertension and diabetes could also have potentially beneficial effects in Alzheimer's disease, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. This article presents a formal consensus evaluation of these drug repositioning opportunities, and highlights several compounds for which sufficient evidence is available to encourage further investigation and potential progression to clinical trials in Alzheimer's disease. Abstract | Full Text | PDF
Advertisement
Cellectis bioresearch’s Cell Line Customization Services Let the renowned gene customization experts modify your cell line at any gene, at any position. Our services include gene modification, knock-out and targeted transgene integration. Benefit from the fastest turnaround time in the market and high cost efficiency. Request more information »
REVIEWS		Top
The spliceosome as a target of novel antitumour drugs Sophie Bonnal, Luisa Vigevani & Juan Valcárcel p847 | doi:10.1038/nrd3823 A number of compounds, derived from bacterial fermentation products, have been found to target subunits of the spliceosome and display anticancer properties. In this Review, Valcárcel and colleagues discuss the role of splicing in cancer and how insights into the mechanism of action of these bacterial compounds might lead to the development of novel antitumour drugs. Abstract | Full Text | PDF
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles Eva van Rooij & Eric N. Olson p860 | doi:10.1038/nrd3864 MicroRNAs (miRNAs) are involved in the regulation of gene expression and have been implicated in the pathology of several diseases. Here, van Rooij and Olson discuss the chemistry of current miRNA inhibitors and evaluate miRNAs as potential therapeutic targets for cardiovascular disorders. Abstract | Full Text | PDF
Article series: Case Histories Vemurafenib: the first drug approved for BRAF-mutant cancer Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Keith Nolop & Peter Hirth p873 | doi:10.1038/nrd3847 Vemurafenib is a small-molecule inhibitor of the oncogenic BRAF kinase approved for the treatment of melanoma. Here, the scientists involved in the discovery of vemurafenib describe the underlying biology of BRAF, the technology used to identify vemurafenib and its clinical development milestones, along with future prospects based on lessons learned during its development. Abstract | Full Text | PDF
Erratum: Targeting the TGFβ signalling pathway in disease Rosemary J. Akhurst & Akiko Hata p886 | doi:10.1038/nrd3878 Full Text | PDF
Erratum: Autism spectrum disorders Sarah Nightingale p886 | doi:10.1038/nrd3892 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.